171 related articles for article (PubMed ID: 30915617)
21. Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer.
Deng K; Zou F; Xu J; Xu D; Luo Z
Mol Carcinog; 2024 Mar; 63(3):524-537. PubMed ID: 38197482
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine elaidate and ONC201 combination therapy inhibits pancreatic cancer in a KRAS mutated syngeneic mouse model.
Mahato R; Kumar V; Sethi B; Staller D
Res Sq; 2023 Jul; ():. PubMed ID: 37503215
[TBL] [Abstract][Full Text] [Related]
23. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.
Awasthi N; Monahan S; Stefaniak A; Schwarz MA; Schwarz RE
Oncotarget; 2018 Jan; 9(4):5274-5286. PubMed ID: 29435178
[TBL] [Abstract][Full Text] [Related]
25. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with LDHA- and MCT4-mediated enhanced glycolysis.
Amrutkar M; Berg K; Balto A; Skilbrei MG; Finstadsveen AV; Aasrum M; Gladhaug IP; Verbeke CS
Cancer Cell Int; 2023 Jan; 23(1):9. PubMed ID: 36658582
[TBL] [Abstract][Full Text] [Related]
27. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
[TBL] [Abstract][Full Text] [Related]
28. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract][Full Text] [Related]
29. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy.
Sun J; Chen Y; Xu J; Song X; Wan Z; Du Y; Ma W; Li X; Zhang L; Li S
Theranostics; 2020; 10(3):1136-1150. PubMed ID: 31938056
[TBL] [Abstract][Full Text] [Related]
30. Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer.
Zhao Y; Zheng Y; Zhu Y; Ding K; Zhou M; Liu T
Int J Pharm; 2023 Apr; 636():122844. PubMed ID: 36925025
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
32. GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells.
Wang L; An Y; Yuan C; Zhang H; Liang C; Ding F; Gao Q; Zhang D
Int J Nanomedicine; 2015; 10():2507-19. PubMed ID: 25848268
[TBL] [Abstract][Full Text] [Related]
33. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
34. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy.
Li J; Chen Y; Zeng L; Lian G; Chen S; Li Y; Yang K; Huang K
J Biomed Nanotechnol; 2016 Aug; 12(8):1654-66. PubMed ID: 29342344
[TBL] [Abstract][Full Text] [Related]
35. Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights.
Iacobazzi RM; Arduino I; Di Fonte R; Lopedota AA; Serratì S; Racaniello G; Bruno V; Laquintana V; Lee BC; Silvestris N; Leonetti F; Denora N; Porcelli L; Azzariti A
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008170
[TBL] [Abstract][Full Text] [Related]
36. Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
Kushwah V; Katiyar SS; Dora CP; Kumar Agrawal A; Lamprou DA; Gupta RC; Jain S
Acta Biomater; 2018 Jun; 73():424-436. PubMed ID: 29649635
[TBL] [Abstract][Full Text] [Related]
37. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
39. Local Sustained Chemotherapy of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel.
Yang D; Ning J; Liao X; Jiang H; Qin S
Int J Nanomedicine; 2023; 18():3989-4005. PubMed ID: 37496690
[TBL] [Abstract][Full Text] [Related]
40. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
